Αποτελέσματα Αναζήτησης
This service is reported with the following HCPCS code: G0476. Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to Pap smear.
Cervical cancer (International Statistical Classification of Diseases and Related Health Problems, 10th revision [ICD-10] code, C53 – Malignant neoplasm of cervix uteri) is the fourth most commonly diagnosed cancer type in women of all ages worldwide (Sung et al., 2021).
Screening is the testing for disease or disease precursors in asymptomatic individuals so that early detection and treatment can be provided for those who test positive for the disease. Use Additional. code to identify any family history of malignant neoplasm (Z80.-) Type 1 Excludes. encounter for diagnostic examination-code to sign or symptom.
Z12.89 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Short description: Encounter for screening for malignant neoplasm of oth sites; The 2025 edition of ICD-10-CM Z12.89 became effective on October 1, 2024.
Z12.4 is a billable diagnosis code used to specify encounter for screening for malignant neoplasm of cervix. Synonyms: cancer cervix screening and fee claim,
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
More recently, an HPV test has been introduced as a screening tool as HPV deoxyribonucleic acid (DNA) is present in almost all cervical cancers and it has demonstrated higher sensitivity for high-grade cervical intraepithelial neoplasia (CIN2+) than that achieved by cytology in several studies.
